Hi Koo.

Agreed. RVX needs a new CEO. It is time for a shareholder focus. They have the financing for the trials in place. Now it is time to leverage the EU approvals and the Hepalink achievement. This is now a drug moving to phase lll BETonMACE trials in the EU and the Territories (China, Hong Kong, Taiwan, Macau).

However, Don spoke with great confidence about phase lll BETonMACE FDA trial approval back in February and there are obvious difficulties currently. I'm surprised that Eastern and NGN have no sway in this regard. I'm also surprised that Eastern and NGN allow Don to carry on. There must be good reasons why they have their money in RVX. Of course getting out at this stage would be difficult to say the least.

What could they do to support investors?

1. A NASDAQ listing as you pointed out.
2. Clear, non ambiguous communications.
3. Better coverage by analysts...RVX are at that stage.
4. Increase breadth of communications coverage.
5. Examine opportunities regarding the share structure.

I really don't want to say it, but I am becoming suspicious about the science primarily because of Don's over promises. Everything else leads me to believe that the science is solid e.g Eastern, NGN, Hepalink, bioassays, epigenetic platform, epigenetics and most of all the proven and replicated increases in ApoA-l (functional HDL) in both ASSURE and SUSTAIN trials.

This company needs a new CEO and they need to hire communications experts.

Sarah did let me know a while back that I should not pay any attention to SH, Agoracom and other non official websites/blogs related to RVX. It is frustrating to say the least.

Toinv